Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety component followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 patients with episodic hepatic encephalopathy in the US and Eastern Europe. The primary efficacy measure will be the proportion of patients who exhibit a hepatic encephalopathy episode during the four-month treatment period.

Source:

Hyperion Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Investigating the changes in severity and epidemiology of respiratory syncytial virus infections among children